Eli Lilly as a sovereign AI leader
The guest argued that Eli Lilly remains a high-conviction compounder due to its early adoption of sovereign AI infrastructure to accelerate drug discovery.
The argument
The speaker emphasized that Eli Lilly has deployed its own sovereign AI capabilities, including a thousand Nvidia Blackwell GPUs on campus, to partner with biotech companies and cure diseases, making it a long-term hold even after massive gains.
The thesis, stress-tested
✓ What validates it
- ✓Clinical trial successes or accelerated drug discovery timelines attributed to their on-campus AI compute
- ✓Expansion of AI-driven partnerships with smaller biotech firms
▸ Risks discussed
- ▸High valuation expectations already priced into the stock
- ▸R&D failures in the biotech pipeline despite AI integration
Hear it yourself
"I I have so much belief in what is happening on the health side and the compounding side of curing diseases, and I wanna be associated with the group that's already done Sovereign AI."
00:00 / 00:12
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE